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We read with interest the report entitled 'Amplification of the TCL1 flanking region at 14q32.1 with peripheral T cell lymphoma' by Sakashita et al in Leukemia. 1 The TCL1 gene was recently identified from the TCL1 locus at 14q32.1, where several breakpoints of 14q32 translocations were found to be clustered, in patients with mature T cell malignancies, such as T cell leukemias developing in cases of Ataxia-telangiectasia (AT) and T cell prolymphocytic leukemia (T-PLL). 2, 3 Adult T cell leukemia (ATL), which is endemic in southwest Japan is a leukemia of peripheral mature T cells. A recent cytogenetic study of 107 ATL cases revealed that (a) chromosomal aberration occurred most frequently in band 14q32, 4 suggesting that TCL1 may be a candidate oncogene involved in the leukemogenesis of ATL. Recently, Narducci et al 5 also reported that the TCL1 gene was overexpressed in all of the ATL specimens they examined. However, these findings are in direct contradiction to our recently published data. 6 We examined TCL1 expression in 21 patients with ATL and five ATL cell lines. Northern blot analysis produced no signals in any of the five ATL cell lines or in 20 of the 21 ATL patients, and only a very faint signal was detected in the remaining patient. 6 These data indicated that TCL1 is not a major target gene for ATL. In contrast, Narducci et al showed with reverse transcriptase-polymerase chain reaction (RT-PCR) and immunostaining that the TCL1 transcript was overexpressed in 10 of 10 ATL cases. 5 Our analysis revealed that almost all B cell tumors, except myelomas, showed very intense TCL1 signals. We also demonstrated that, in normal human tissues, TCL1 expression is seen in the spleen, lymph nodes and peripheral blood lymphocytes (PBL), but not in the thymus, suggesting that TCL1 is transcribed predominantly in lymphoid cells of B cell lineage. 6 Indeed, cell fractionation analysis using anti-CD19 beads demonstrated that the TCL1 signal was found in CD19-positive cells in PBL. Thus, it should be emphasized that TCL1 expression in ATL specimens needs to be more carefully investigated because contamination by B cells might generate positive signals when the highly sensitive RT-PCR method is used for analysis.
Our study did not rule out that TCL1 could be one of the target genes in a given type of T cell malignancy, because one of our three T-PLL patients showed significant TCL1 expression. 6 This suggests that some types of T cell malignancies, such as T-PLL and T cell leukemias arising from cases of AT, might aberrantly express TCL1 as a result of TCL1 gene alterations. Recently, Sakashita et al also reported 20 cases of peripheral T cell lymphoma (PTL), a mature T cell tumor, at a similar stage of differentiation to T-PLL and ATL.
1 They found one case of PTL with amplification at the TCL1 locus by two-color fluorescent in situ hybridization, but RT-PCR did not exhibit any TCL1 signals. Because of these conflicting findings, the TCL1 gene, a candidate oncogene for certain types of T cell malignancy, warrants a more careful re-evaluation to determine whether it is a target gene for ATL.
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